Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anasua Chakraborty

Pulmonary Disease Danbury, CT Medical Doctor

NPI 1952614919 CMS profile 1380482

33 Germantown Rd, Fl 1, Danbury, CT 06810

Open in the dashboard

General payments

$4,455

206 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anasua Chakraborty of Danbury, CT is reported in the CMS Open Payments database as having received $4,455 across 206 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $168 4
2024 General $266 4
2023 General $968 41
2022 General $1,238 55
2021 General $865 44
2020 General $497 31
2019 General $453 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anasua Chakraborty
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Anasua Chakraborty were reported at $168. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Anasua Chakraborty Pulmonary Disease median Middle half National median
2019 $453 $377 $109–$1,340 $163
2020 $497 $230 $56–$907 $114
2021 $865 $269 $68–$1,072 $132
2022 $1,238 $390 $100–$1,457 $149
2023 $968 $419 $114–$1,659 $160
2024 $266 $476 $123–$1,818 $164
2025 $168 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,556 101 payments
  2. Actelion Pharmaceuticals US, Inc. $447 9 payments
  3. Mallinckrodt Hospital Products Inc. $346 9 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $306 12 payments
  5. Regeneron Healthcare Solutions, Inc. $248 10 payments
  6. Genzyme Corporation $193 9 payments
  7. Mylan Specialty L.P. $160 3 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $113 5 payments
  9. Jazz Pharmaceuticals Inc. $104 5 payments
  10. Harmony Biosciences LLC $100 1 payment
  11. Other $883 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,899 200 payments
  2. Education $556 6 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $971 60 payments
  2. OPSUMIT $422 8 payments
  3. NUCALA $368 20 payments
  4. ACTHAR $346 9 payments
  5. UPTRAVI $343 6 payments
  6. DUPIXENT Inflammation And Immunology $248 10 payments
  7. YUPELRI $160 3 payments
  8. GLASSIA $145 7 payments
  9. DUPIXENT Immunology $142 7 payments
  10. XYWAV $104 5 payments
  11. Other $1,581 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

2,613

Median for Pulmonary Disease: 936

Drug cost

$1,132,322

Median for Pulmonary Disease: $487,987

Branded share of claims

64%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 377 $337,079
Wakix Pitolisant Hcl Brand 11 $157,209
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 162 $109,498
Breo Ellipta Fluticasone/Vilanterol Brand 181 $106,259
Tezspire Tezepelumab-Ekko Brand 17 $77,345
Dupixent Pen Dupilumab Brand 13 $49,764
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 57 $44,337
Xolair Omalizumab Brand 13 $38,868
Symbicort Budesonide/Formoterol Fumarate Brand 94 $34,269
Eliquis Apixaban Brand 36 $26,888

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$113,737

Medicare's payments for the services billed

Medicare patients

676

Average age 75

Services billed

1,707

321 women, 355 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 41%
COPD 41%
Atrial fibrillation 31%
Diabetes 29%
Chronic kidney disease 29%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
YUPELRI
  • Mylan Specialty L.P. $146
$146 — —
DUPIXENT
  • GENZYME CORPORATION $30
$30 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

206 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record